From barretjs@a1.lldmpc.umc.dupont.com Thu Dec 12 10:25:15 1996
Subject: Blinding Issues

NMUSERS,

I would like to solicit the assistance of the group to address the issue of blinding in Phase-IIa-b / III trials with respect PK/PD, covariate, and outcome (primary, secondary measures) data. The goal of my querry is to ascertain the reasonable extremes a company should go through to maintain the blind with those who would analyze population-based PK/PD data. The grey area lies in the Phase-IIa/b setting in which the designation of pivotal trial status may be sought based on the inclusion of primary outcome variable in the study design. The issue comes when secondary markers believed to be suggestive of these outcomes are supplied to the pharmacokineticist and/or statistician while the study is ongoing. Some are of the opinion that this jeopardizes the integrity of the study. While I don t want to weigh the merits of conservative versus liberal approaches to study blinding, I have the following basic questions:

(1) Assuming the analysis to be completed by those who have access to PK data, what, if any, are the reservations with supplying the following data types?:
(a) demographic data
(b) clinical labs (assuming that lab results may indicate who is on drug)
(c) surrogate marker data (biochemical marker, genotyping results, etc.)
(d) pharmacodynamic data
(e) secondary outcome data (not used to power study)
(f) primary outcome data (used to power study and declared as such in the protocol)

(2) Are there blinding procedures in place to insure the integrity of the study with respect to this type of analysis?

(3) Is there an SOP which guides such procedures? If so,
(a) Which parts of question 1 are covered?
(b) Is the SOP common to all studies or specific to a particular study?
(c) Has the SOP been submitted to FDA?

(4) What is the best way (or reasonable ways) to report (a) suspect data or (b) data suggesting a safety concern by groups with access to such data ?

I welcome any and all comments which address these questions or others which may be of peripheral interest to the group.

Jeff Barrett, Ph.D.
Principal Research Scientist
DuPont Merck Pharmaceuticals